NEW YORK (GenomeWeb News) – Horizon Discovery today announced it has signed an agreement with Bayer Pharma for the use of Horizon's Genesis genome editing technology in support of Bayer's cancer R&D programs.

Horizon will use its platform to develop human isogenic cell lines for use in Bayer's programs in order to deliver cell lines that more accurately model the disease-relevant mutations found in human tumors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.